NanoLogix Announces Expansion of EPA Work on Rapid Tests for Drinking Water Quality and Provides Update on Publication of Group B Streptococcus Trial

HUBBARD, Ohio--NanoLogix (OTC MARKETS: NNLX), a biotechnology innovator in the rapid detection and identification of live-cell bacteria and microorganisms, announced today the U.S. Environmental Protection Agency (EPA) intends to expand its Cooperative Research And Development Agreement (CRADA) with NanoLogix to include additional water-borne pathogens. To accommodate the additional research, the company will add two scientists to its staff at its Cincinnati laboratory. More information on the NanoLogix CRADA can be found at the EPA MCEARD News Archive where an article on the company's work can be found two-thirds down the page.

University of Texas Health Science Center - Houston Group B Streptococcus Update

NanoLogix is pleased to announce Phase I of the Group B Strep research utilizing NanoLogix technology is expected to be published by the end of August, 2011 in a major peer-reviewed American medical journal. In addition, lead researcher on the UTHSC-Houston clinical trial, Dr. Jonathan Faro M.D., Ph.D., assistant professor in General Obstetrics & Gynecology at UTHSC-Houston, will present these Phase I findings at the Central Association of Obstetricians and Gynecologists Annual Meeting on October 26-29, 2011. Results of the completed UTHSC Phase II trial are currently being prepared for publication. Meanwhile, the final phase of the 300-patient clinical trial (constituting Phase III of the Group B Strep trial) is on-going and nearing completion.

NanoLogix In the News

Recently, NanoLogix technology has been featured prominently in several media outlets, including:

About NanoLogix, Inc.

NanoLogix is a biotechnology company focused primarily on rapid diagnostics. Its products offer accelerated detection and identification of microorganisms. In addition to medical and homeland security applications, NanoLogix technology is applicable in pharmaceutical, industrial, veterinary and environmental testing. Patents granted to NanoLogix can be used in the areas of applied microbiology, soil microbiology and bioremediation, microbial physiology, molecular biology, pharmacology, pharmaco-kinetics, and antibiotic sensitivity. For more information visit

This press release contains statements, which may constitute "forward- looking statements" within the meaning of the Securities Act of 1933 and the Securities Exchange Act of 1934, as amended by the Private Securities Litigation Reform Act of 1995. Those statements include statements regarding the intent, belief or current expectations of NanoLogix, Inc., and members of its management as well as the assumptions on which such statements are based. Prospective investors are cautioned that any such forward-looking statements are not guarantees of future performance and involve risks and uncertainties, and that actual results may differ materially from those contemplated by such forward-looking statements. The Company undertakes no obligation to update or revise forward-looking statements to reflect changed assumptions, the occurrence of unanticipated events or changes to future operating results.


Media Contact:
Technica Communications
Lisa Ann Pinkerton, 650-288-1824
Investor Contact:
NanoLogix, Inc.
Carol Surrena, 330-534-0800